Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival

International Journal of Cancer

Volumn 115, Issue 6, 2005, Pages 911-916

  Hasumi, Hisashi ^a   Ishiguro, Hitoshi ^a   Nakamura, Masashi ^a   Sugiura, Shinpei ^a   Osada, Yutaka ^a   Miyoshi, Yasuhide ^a   Fujinami, Kiyoshi ^a   Yao, Masahiro ^a   Hamada, Kenji ^b   Yamada Okabe, Hisafumi ^b   Kubota, Yoshinobu ^a   Uemura, Hiroji ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Neuroserpin (PI 12); Prostate cancer; Real time PCR

Indexed keywords

NEUROSERPIN; PROTEINASE INHIBITOR; PROTEINASE INHIBITOR 12; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER PROGRAM; CONTROLLED STUDY; DEVICE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; UPREGULATION;

DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEUROPEPTIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATIC NEOPLASMS; SERPINS; SURVIVAL RATE; UP-REGULATION;

EID: 20344378684     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20967     Document Type: Article

References (24)

1. Research Group for Population-Based Cancer Registration in Japan. Cancer incidence in Japan. In: Tajima K, Kuroishi T, Oshima A. Cancer mortality and morbidity statistics. Tokyo: S. Karger AG, 2004; 51:95-130.
2. Ishiguro H, Uemura H, Fujinami K, Ikeda N, Ohta S, Kubota Y. 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. Int J Cancer 2003;105:26-32.
3. Fujinami K, Uemura H, Ishiguro H, Kubota Y. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP. Int J Mol Med 2002;10:173-6.
4. Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, et al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 2003;63: 6387-94.
5. Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, et al. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-12.
6. Shen-Ong GL, Feng Y, Troyer DA. Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology. Cancer Res 2003;63:3296-301.
7. Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, Kitaraura H, Kubota Y. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003;56:280-6.
8. Chang WS, Chang NT, Lin SC, Wu CW, Wu FY. Tissue-specific cancer-related serpin gene cluster at human chromosome band 3q26. Genes Chromosomes Cancer 2000;27:240-55.
9. Okamoto M, Lee C, Oyasu R. Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCaP: role of interleukin-6. Endocrinology 1997;138:5071-4.
10. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-AKT, STAT3, and MAPK, these distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003;305:462-9.
11. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgen stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9: 2416-25.
12. Hill RM, Parker PK, Coates LC, Mezey E, Pearson JF, Birch NP. Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AT-20 cells. Biochem J 2000;345:595-601.
13. Berger P, Kozlov SV, Cinelli P, Kruger SR, Vogt L, Sonderegger P. Neuronal depolarization enhances the transcription of the neuronal serine protease inhibitor neuroserpin. Mol Cell Neurosci 1999;14: 455-67.
14. Hastings GA, Coleman TA, Haudenschild CC, Stefansson S, Smith EP, Barthlow R, Cherry S, Sandkvist M, Lawrence DA. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. J Biol Chem 1997;272:33062-7.
15. Houenou LJ, Turner PL, Li L, Oppenheim RW, Festoff BW. A serine protease inhibitor, protease nexin I, rescues motoneurons from naturally occurring and axotomy-induced cell death. Proc Natl Acad Sci USA 1995;92:895-9.
16. Osterwalder T, Contartese J, Stoeckli ET, Kuhn TB, Sonderegger P. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J 1996;15;2944-53.
17. Schrimpf SP, Bleiker AJ, Brecevic L, Kozlov SV, Berger P, Osterwalder T, Krueger SR, Schinzel A, Sonderegger P. Human neuroserpin (PI12): cDNA cloning and chromosomal localization to 3q26. Genomics 1997;40:55-62.
18. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000;96: 569-76.
19. Vaughan PJ, Pike CJ, Cotman CW, Cunningham DD. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 1995;15:5389-401.
20. Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, Osterwalder T, Rulicke T, Sonderegger P. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 2001;18:443-57.
21. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002; 106:740-5.
22. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533-40.
23. Hill RM, Coates LC, Parmar PK, Mezey E, Pearson JF, Birch NP. Expression and functional characterization of the serine protease inhibitor neuroserpin in endocrine cells. Ann NY Acad Sci 2002; 971:406-15.
24. Tor H, Anders J, Nima H, Elisabeth P, Sophie DF. Neuroendocrine serum tumor markers in hormone-resistant prostate cancer. Eur Urol 2003;44:215-21.